Firebrick Pharma Private Placement Dilutes Major Shareholder’s Voting Power

Firebrick Pharma Limited ( (AU:FRE) ) just unveiled an announcement.

Firebrick Pharma has disclosed a change in the voting power of substantial shareholder Peter Laurence Molloy and his related parties, following a private placement completed on 31 March 2026. While Molloy and associated entities continue to hold 31,811,017 fully paid ordinary shares, their voting power has fallen from 12.74% to 11.17% due to dilution from the new share issuance.

The notice details that Molloy’s interest is held through Aquarico Pty Ltd and Christine Louise Molloy, over which he has effective voting control under Australian corporations law. The reduced percentage stake, despite unchanged absolute holdings, highlights the impact of the company’s capital raising on existing major shareholders and the evolving ownership structure of Firebrick Pharma.

More about Firebrick Pharma Limited

Firebrick Pharma Limited is a listed pharmaceutical company focused on developing and commercialising healthcare products. The company operates in the life sciences sector, where equity placements and changes in substantial shareholdings can materially affect control dynamics and funding capacity.

Average Trading Volume: 91,873

Technical Sentiment Signal: Buy

Current Market Cap: A$18.37M

See more insights into FRE stock on TipRanks’ Stock Analysis page.